Boston Scientific Symbiot
This article was originally published in The Gray Sheet
Covered stent system for saphenous vein graft disease debuts in Europe following CE mark approval. The self-expanding nitinol stent, which is encased in a thin, porous ePTFE polymer membrane, decreases plaque embolization during the stenting procedure and reduces restenosis, according to the firm. Symbiot III, a 700-patient, multicenter, U.S. randomized clinical trial is underway, and FDA approval is expected in early 2004...
You may also be interested in...
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.